P B Chapman

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Clinical results using biochemotherapy as a standard of care in advanced melanoma
    P B Chapman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY 10021, USA
    Melanoma Res 12:381-7. 2002
  2. pmc Cross-presentation of disialoganglioside GD3 to natural killer T cells
    Dianna Y Wu
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 198:173-81. 2003
  3. ncbi request reprint Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody
    Paul B Chapman
    Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Investig Drugs 4:710-5. 2003
  4. ncbi request reprint Melanoma vaccines
    Paul B Chapman
    Melanoma Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Semin Oncol 34:516-23. 2007
  5. ncbi request reprint A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside
    Paul B Chapman
    Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Vaccine 22:2904-9. 2004
  6. ncbi request reprint Counterpoint: The case against adjuvant high-dose interferon-alpha for melanoma patients
    Paul B Chapman
    Melanoma Section, Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer, 1275 York Avenue, Room K718, New York, NY 10021 6007, USA
    J Natl Compr Canc Netw 2:69-72. 2004
  7. pmc Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    Paul B Chapman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 364:2507-16. 2011
  8. ncbi request reprint Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside
    Paul B Chapman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:4717-23. 2004
  9. ncbi request reprint Immunotherapy of melanoma
    Paul B Chapman
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Chemother Biol Response Modif 20:371-83. 2002
  10. ncbi request reprint Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide
    J J Lewis
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Int J Cancer 87:391-8. 2000

Research Grants

Detail Information

Publications45

  1. ncbi request reprint Clinical results using biochemotherapy as a standard of care in advanced melanoma
    P B Chapman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY 10021, USA
    Melanoma Res 12:381-7. 2002
    ..The low response rate among previously treated patients indicates that biochemotherapy is not useful as second-line therapy...
  2. pmc Cross-presentation of disialoganglioside GD3 to natural killer T cells
    Dianna Y Wu
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 198:173-81. 2003
    ..This is the first analysis of a natural ligand for mouse NKT cells and the first definitive paper of cross-presentation to NKT cells. This could be a mechanism for NKT cell recognition of tumor gangliosides in CD1- tumors...
  3. ncbi request reprint Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody
    Paul B Chapman
    Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Investig Drugs 4:710-5. 2003
    ..A phase III trial is underway in SCLC patients to determine the effects of BEC2 on overall survival...
  4. ncbi request reprint Melanoma vaccines
    Paul B Chapman
    Melanoma Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Semin Oncol 34:516-23. 2007
    ..Once a relevant clinical response can be induced, it should be possible to develop validated immunoassays that will direct future melanoma vaccine development...
  5. ncbi request reprint A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside
    Paul B Chapman
    Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Vaccine 22:2904-9. 2004
    ..5 mg dose used in previous BEC2 trials. Prolonged booster immunizations did not induce or maintain antibody responses...
  6. ncbi request reprint Counterpoint: The case against adjuvant high-dose interferon-alpha for melanoma patients
    Paul B Chapman
    Melanoma Section, Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer, 1275 York Avenue, Room K718, New York, NY 10021 6007, USA
    J Natl Compr Canc Netw 2:69-72. 2004
    ..New treatment options are needed for adjuvant therapy of melanoma. In the meantime, the data from the randomized trials make it difficult for many clinicians and patients to have enthusiasm for adjuvant HD IFN...
  7. pmc Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    Paul B Chapman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 364:2507-16. 2011
    ..Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation...
  8. ncbi request reprint Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside
    Paul B Chapman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:4717-23. 2004
    ..Future multivalent ganglioside vaccines should include the GD3-L-KLH vaccine...
  9. ncbi request reprint Immunotherapy of melanoma
    Paul B Chapman
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Chemother Biol Response Modif 20:371-83. 2002
  10. ncbi request reprint Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide
    J J Lewis
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Int J Cancer 87:391-8. 2000
    ..1/2,000 in the second patient. These results demonstrate that modest expansion of peptide-specific CD8(+) T cells can be generated in vivo by immunization with peptide plus QS-21 in at least a subset of patients with melanoma...
  11. ncbi request reprint High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696
    J M Kirkwood
    University of Pittsburgh Medical Center, University of Pittsburgh Cancer Institute Melanoma Center, Department of Medicine, Division of Hematology Oncology, Pittsburgh, PA, USA
    J Clin Oncol 19:1430-6. 2001
    ....
  12. ncbi request reprint Phase II trial of neoadjuvant temozolomide in resectable melanoma patients
    G D Shah
    Department of Medicine, Sloan Kettering Cancer Center, New York, NY, USA
    Ann Oncol 21:1718-22. 2010
    ..A secondary objective was to test the feasibility of obtaining adequate tissue before and after treatment for genetic testing...
  13. doi request reprint Antibody response to GD3 ganglioside is independent of NKT cells
    J E Park
    Department of Medicine and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cytotherapy 10:38-44. 2008
    ..But the ability of NKT cells to modulate B-cell responses to tumor glycolipids that are themselves recognized by NKT cells has not been explored...
  14. ncbi request reprint Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients
    M V Dhodapkar
    Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, New York 10021, USA
    Clin Cancer Res 6:4831-8. 2000
    ....
  15. doi request reprint Histology and outcomes of newly detected lung lesions in melanoma patients
    E C Smyth
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, USA
    Ann Oncol 23:577-82. 2012
    ..Melanoma frequently metastasizes to the lung. Improved radiologic techniques may decrease the need for biopsy of such lesions. The aim of this study was to examine factors predictive of a positive biopsy of melanoma...
  16. ncbi request reprint Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15
    T Takahashi
    Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021
    J Immunol 154:772-9. 1995
    ..Thus, by cytotoxicity assays, shared Ags were only recognized on melanoma cells but not on normal melanocytes. In summary, this analysis shows that melanoma cells share an Ag that is presented by HLA-DR15...
  17. ncbi request reprint Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901
    John D Roberts
    Virginia Commonwealth University, Richmond, Virgina 23298 0037, USA
    J Immunother 29:95-101. 2006
    ..The combination of g209-2M and low-dose IL-2 is safe and tolerable but inactive against advanced melanoma. Absence of evidence of immunization raises concerns for peptide-based immunization strategies with concurrent IL-2...
  18. ncbi request reprint Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma
    Wen Jen Hwu
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 106:2445-51. 2006
    ..Therefore, the efficacy and safety of temozolomide in combination with pegylated IFN-alpha-2b in patients with metastatic melanoma without brain metastases was investigated...
  19. ncbi request reprint Immunotherapy of melanoma
    Petra Rietschel
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hematol Oncol Clin North Am 20:751-66. 2006
    ..This article reviews the recent clinical results of trials exploring different immunotherapy strategies against melanoma...
  20. ncbi request reprint When you look matters: the effect of assessment schedule on progression-free survival
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, 3rd Fl, New York, NY 10021, USA
    J Natl Cancer Inst 99:428-32. 2007
    ..The decision to use PFS as a primary endpoint should be made carefully when designing clinical trials, and investigators focused on a particular disease should develop consensus standards and strive for consistent surveillance intervals...
  21. ncbi request reprint Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma
    Jedd D Wolchok
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 15:2044-50. 2007
    ..Mouse and human TYR DNA vaccines were found safe and induced CD8(+) T-cell responses in 7 of 18 patients. T cells recognizing a native TYR peptide had a phenotype consistent with that of effector memory cells...
  22. doi request reprint Phase II study of extended-dose temozolomide in patients with melanoma
    Petra Rietschel
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 26:2299-304. 2008
    ..We hypothesized that expression of methylguanine methyltransferase (MGMT) in the tumor would correlate with drug resistance to TMZ...
  23. ncbi request reprint Adjuvant therapy of melanoma
    Gaurav D Shah
    Department of Medicine, Melanoma Sarcoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    Cancer J 13:217-22. 2007
    ..The purpose of this article was to review the current state of knowledge regarding the efficacy of adjuvant therapy for melanoma...
  24. doi request reprint Combining a peptide vaccine with high-dose interleukin-2
    Paul B Chapman
    J Clin Oncol 26:2250-1. 2008
  25. ncbi request reprint Detection of melanoma cells in sentinel lymph nodes by PCR is not yet ready for prime time
    Paul B Chapman
    Pigment Cell Res 20:343-4. 2007
  26. pmc Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand
    Jun Eui Park
    Department of Medicine, Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Immunology 123:145-55. 2008
    ..We found that this suppression was not mediated by soluble factors. We hypothesize that GM3 induces changes to the APC that lead to suppression of T helper type 2-like NKT-cell responses...
  27. ncbi request reprint Variates of survival in metastatic uveal melanoma
    Petra Rietschel
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:8076-80. 2005
    ..We evaluated the survival of our patients with metastatic uveal melanoma, described factors that correlated with survival, and evaluated the influence of screening tests on time of detection and survival...
  28. ncbi request reprint T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants
    Susanne G Schaed
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:967-72. 2002
    ....
  29. ncbi request reprint Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial
    Wen Jen Hwu
    Departments of Medicine, Epidemiology and Biostatistics, and Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2610-5. 2002
    ..To establish a safe and tolerated regimen of an oral cytotoxic agent, temozolomide, and a cytostatic agent, thalidomide, in patients with unresectable stage III or IV malignant melanoma...
  30. ncbi request reprint Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope
    Jedd D Wolchok
    J Clin Oncol 20:3176; author reply 3176-7. 2002
  31. ncbi request reprint An optimal two-stage phase II design utilizing complete and partial response information separately
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Control Clin Trials 23:367-79. 2002
    ..Sample size tables are provided for parameter sets commonly used in the oncologic setting. Software is available by contacting the authors...
  32. ncbi request reprint Vaccinating patients with autologous tumor
    Paul B Chapman
    J Clin Oncol 20:4139-40. 2002
  33. ncbi request reprint How can we tell when cancer vaccines vaccinate?
    Jedd D Wolchok
    J Clin Oncol 21:586-7. 2003
  34. ncbi request reprint Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma
    Jedd D Wolchok
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Melanoma Res 13:189-96. 2003
    ..The observation of two partial responses has led to a phase II study to evaluate treatment with high dose paracetamol alone or in combination with BCNU...
  35. ncbi request reprint Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma
    Wen Jen Hwu
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:3351-6. 2003
    ..To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases...
  36. ncbi request reprint Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21
    Govind Ragupathi
    Laboratory of Tumor Vaccinology, Clinic Immunology Service, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:5214-20. 2003
    ..However, vaccination of patients with GD2-KLH has previously failed to induce a consistent relevant antibody response. We test here whether the use of GD2 lactone-KLH can overcome the low immunogenicity of GD2-KLH...
  37. ncbi request reprint Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications
    Y B Su
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:610-6. 2004
    ..Using an extended dosing schedule, we noted a high incidence of lymphopenia and occasional opportunistic infections (OIs). Here we report our retrospective experience in the first 97 patients...
  38. ncbi request reprint Defining adequate surgery for primary melanoma
    Susan E Krown
    N Engl J Med 350:823-5. 2004
  39. ncbi request reprint T-cell chauvinists versus antibody advocates--can't we all just get along?
    Paul B Chapman
    J Clin Oncol 22:4446-8. 2004
  40. ncbi request reprint Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study
    Wen Jen Hwu
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 103:2590-7. 2005
    ..The current Phase II study examined the efficacy and safety of this combination in chemotherapy-naive patients with brain metastases...
  41. ncbi request reprint Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses
    Miguel A Perales
    Department of Medicine and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Chemother Biol Response Modif 22:749-60. 2005
  42. ncbi request reprint Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)
    Giuseppe Giaccone
    Division of Medical Oncology, Vrije Universiteit Medical Center, 1117 De Boelelaan, Amsterdam, The Netherlands
    J Clin Oncol 23:6854-64. 2005
    ..We assessed whether Bec2/bacille Calmette-Guerin (BCG) vaccination prolongs survival in patients with limited-disease small-cell lung cancer (SCLC) after a major response to chemotherapy and chest radiation...
  43. ncbi request reprint Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients
    Virginia M Klimek
    Memorial Sloan Kettering Cancer Center, Department of Medicine, Clinical Immunology Service, New York, NY, USA
    Cytokines Cell Mol Ther 7:71-4. 2002
    ..In this series, serum MIA was not a sensitive marker for relapse in patients who were clinically free of disease after treatment...
  44. pmc Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma
    Molly Yancovitz
    Department of Dermatology, New York University School of Medicine, 550 First Ave, H 100, New York, NY 10016, USA
    J Mol Diagn 9:178-83. 2007
    ..The assay detected mutant BRAF alleles in plasma samples from 14 of 26 (54%) metastatic melanoma patients. These data demonstrate the feasibility of blood-based testing for BRAF mutations in metastatic melanoma patients...
  45. ncbi request reprint Helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b
    Karen E Hurley
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 10:739-42. 2005
    ..In this paper, we evaluate the benefits and risks of adjuvant high-dose interferon-alpha2b and try to provide a framework to help oncologists guide patients trying to decide whether to undergo adjuvant high-dose interferon therapy...

Research Grants6

  1. Anti-GD3 NKT cells as effector cells against melanoma
    Paul Chapman; Fiscal Year: 2004
    ..This will provide initial support for an immunotherapeutic approach based on antigen-specific NKT cells. ..
  2. IMMUNIZATION AGAINST TUMOR CELL ANTIGENS
    Paul Chapman; Fiscal Year: 2003
    ..This close mentoring relationship reflects our current teaching paradigm. The grant award will provide the PI with more time to conduct the clinical trials and to mentor additional beginning clinical investigators. ..
  3. Anti-GD3 NKT cells as effector cells against melanoma
    Paul Chapman; Fiscal Year: 2003
    ..This will provide initial support for an immunotherapeutic approach based on antigen-specific NKT cells. ..
  4. Anti-GD3 NKT cells as effector cells against melanoma
    Paul Chapman; Fiscal Year: 2005
    ..This will provide initial support for an immunotherapeutic approach based on antigen-specific NKT cells. ..
  5. Anti-GD3 NKT cells as effector cells against melanoma
    Paul Chapman; Fiscal Year: 2006
    ..This will provide initial support for an immunotherapeutic approach based on antigen-specific NKT cells. ..
  6. Phase II trial of 17-AAG in melanoma patients
    Paul Chapman; Fiscal Year: 2007
    ..As an exploratory analysis, we will compare expression patterns in pre-treatment vs. post-treatment specimens, clinically responding tumors vs. non-responding tumors, and mutant BRAF vs. wild-type BRAF tumors. ..